Skip to content

Validation of the Hebrew Version of the Montreal Affective Voices.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01512732
Enrollment
120
Registered
2012-01-19
Start date
2012-02-29
Completion date
Unknown
Last updated
2012-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Parkinson's Disease

Brief summary

Today, no non-verbal auditory stimuli that assess mental processing are available in Israel. The goal of this study is to make available a validated set of auditory stimuli in Israel. We created a computerized Hebrew version of the Montreal Affective Voices (MAV). The MAV is a novel tool for assessing mental processing. The MAV consists of 90 nonverbal affect bursts corresponding to nine different emotions (such as anger, fear, happiness etc.) recorded by ten different actors. The uniqueness of these affective bursts is that they do not contain verbal context, but rather express affective moods using the vowel /a/ (as in apple). In this study, the investigators will verify the new Hebrew version of MAV in healthy control groups. Next, the investigators will compare the mental processing ability in young vs. old population, using the MAV test. In addition, the investigators will assess mental processing in two pathologic study groups (Parkinson's disease, major depressive disorder) using the MAV test. The investigators intend to use the MAV tool in future research in Parkinson's disease and depression.

Interventions

None listed

Sponsors

Hadassah Medical Organization
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy group * Parkinson's disease * Major depressive disorder * All participants will be competent and willing to give written informed consent. Patients over 65 and/or suspected to have a cognitive decline will be tested by the Mini-mental test and will be included in the study only if the score is above 26.

Exclusion criteria

* Non-competent or unable to give written informed consent

Design outcomes

Primary

MeasureTime frame
Verifying the results achieved by Belin et al (2008) when using the Hebrew version of the MAV bursts in healthy control groups.12 months

Countries

Israel

Contacts

Primary ContactRenana Eitan, Dr
renanaeitan@gmail.com972-050-4048165

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026